Used primarily as a potent carbonic anhydrase inhibitor, this compound shows significant application in the treatment of glaucoma by reducing intraocular pressure. It acts by inhibiting carbonic anhydrase II and IX isoforms, which decreases aqueous humor production in the eye. Due to its sulfonamide group and strong binding affinity to the enzyme active site, it is also investigated for antitumor activity, particularly in hypoxic tumors where carbonic anhydrase IX is overexpressed. Additionally, it has been explored for use in anti-epileptic and anti-obesity research owing to central nervous system effects observed in preclinical studies. Its structural properties make it a valuable scaffold in medicinal chemistry for designing isoform-selective inhibitors.